Anti-Angiogenic Therapy: Current Challenges and Future Perspectives
Open accessThe DOI matches its Crossref record; 242 of the 246 references it cites were found in a registry or an index.
Abstract
Anti-angiogenic therapy is an old method to fight cancer that aims to abolish the nutrient and oxygen supply to the tumor cells through the decrease of the vascular network and the avoidance of new blood vessels formation. Most of the anti-angiogenic agents approved for cancer treatment rely on targeting vascular endothelial growth factor (VEGF) actions, as VEGF signaling is considered the main angiogenesis promotor. In addition to the control of angiogenesis, these drugs can potentiate immune therapy as VEGF also exhibits immunosuppressive functions. Despite the mechanistic rational that strongly supports the benefit of drugs to stop cancer progression, they revealed to be insufficient in most cases. We hypothesize that the rehabilitation of old drugs that interfere with mechanisms of angiogenesis related to tumor microenvironment might represent a promising strategy. In this review, we deepened research on the molecular mechanisms underlying anti-angiogenic strategies and their failure and went further into the alternative mechanisms that impact angiogenesis. We concluded that the combinatory targeting of alternative effectors of angiogenic pathways might be a putative solution for anti-angiogenic therapies.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures



Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Tyrosine kinase inhibitors (TKIs) have broadened the scope of anti-angiogenic therapy to include other pro-angiogenic growth factors and receptors such as PDGFR, FGFR, c-MET, and PIGF, which are now mainstay targets of the targeted therapy arsenal (Table 2) [33].”
From The HIF Axes in Cancer - Angiogenesis, Metabolism and Immune-Modulation (2025) · cites this paper as [33]
Experimental — accuracy not yet measured
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
1 retracted
Park, S. Y., Kang, J. H., Jeong, K. J., Lee, J., Han, J. W., Choi, W. S., Kim, Y. K., Kang, J., Park, C. G., & Lee, H. Y. (2011) · International Journal of Cancer · doi:10.1002/ijc.25589 · Cited by 135
RetractedHallmarks of Cancer: The Next Generation
Hanahan, D., & Weinberg, R. A. (2011) · Cell · doi:10.1016/j.cell.2011.02.013 · Cited by 66,590
Tumor angiogenesis: therapeutic implications
Sherwood, L. M., Parris, E. E., & Folkman, J. (1971) · New England Journal of Medicine · doi:10.1056/nejm197111182852108 · Cited by 10,187
Molecular mechanisms and clinical applications of angiogenesis
Carmeliet, P., & Jain, R. K. (2011) · Nature · doi:10.1038/nature10144 · Cited by 5,467 · cited 2×
“The blockage of the VEGF:VEGFR axis seems to be ineffective as monotherapy, and primary or de novo resistance is a common feature in cancer patients [23,123].”
BackgroundCancer drug resistance: an evolving paradigm
Holohan, C., Van Schaeybroeck, S., Longley, D. B., & Johnston, P. G. (2013) · Nature Reviews Cancer · doi:10.1038/nrc3599 · Cited by 4,681
Endostatin: an endogenous inhibitor of angiogenesis and tumor growth
O'Reilly, M. S., Boehm, T., Shing, Y., Fukai, N., Vasios, G., Lane, W. S., Flynn, E., Birkhead, J. R., Olsen, B. R., & Folkman, J. (1997) · Cell · doi:10.1016/s0092-8674(00)81848-6 · Cited by 4,486 · cited 1×
“These strategies have focused mainly on eye disease [110] and wound healing [111], but their application in cancer therapy is under debate [112,113].”
BackgroundAtezolizumab for First-Line Treatment of Metastatic Nonsquamous NSCLC
Socinski, M. A., Jotte, R. M., Cappuzzo, F., Orlandi, F., Stroyakovskiy, D., Nogami, N., Rodríguez-Abreu, D., Moro-Sibilot, D., Thomas, C. A., Barlesi, F., et al. (2018) · New England Journal of Medicine · doi:10.1056/nejmoa1716948 · Cited by 3,733 · cited 1×
“on tumor growth and an increase in OS [161].”
BackgroundVascular-specific growth factors and blood vessel formation
Yancopoulos, G. D., Davis, S., Gale, N. W., Rudge, J. S., Wiegand, S. J., & Holash, J. (2000) · Nature · doi:10.1038/35025215 · Cited by 3,699
Kim, K. J., Li, B., Winer, J., Armanini, M., Gillett, N., Phillips, H. S., & Ferrara, N. (1993) · Nature · doi:10.1038/362841a0 · Cited by 3,605 · cited 1×
“Moreover, the design and development of new anti-VEGF signaling drugs continues, including the arylamide-5-anilinoquinazoline-8nitro derivative a recent inhibitor of VEGFR2-kinase activity with in vitro anti-tumor and anti-angiogenic activity [38].”
BackgroundFundamental Mechanisms of Immune Checkpoint Blockade Therapy
Wei, S. C., Duffy, C. R., & Allison, J. P. (2018) · Cancer Discovery · doi:10.1158/2159-8290.cd-18-0367 · Cited by 3,088
Research works printed but not linked: 1
- 5. Domingues, G.; Fernandes, S.G.; Serpa, J. Dynamics of VEGF-A and its Receptors in Cancer Vascularization-An Overview. In Understand Cancer: Research and Treatment ; iConcept Press: Hong Kong, China, Chapter 3; 2015; ISBN 978-1-922227-386.
Cited by
Items 201–300 of 428
Xie, Z., Qin, Y., Chen, X., Yang, S., Yang, J., Gui, L., Liu, P., He, X., Zhou, S., Zhang, C., et al. (2024) · Targeted Oncology · doi:10.1007/s11523-024-01057-w · Cited by 5
Guo, M., Sun, Y., Wang, X., Wang, Z., Yuan, X., Chen, X., Yuan, X., & Wang, L. (2024) · International Journal of Molecular Sciences · doi:10.3390/ijms251910486 · Cited by 6
“The main principle of antiangiogenic drugs is to act on the targets of angiogenesis, interfere with the key signaling pathways of protumor angiogenesis, downregulate the expression of proangiogenic factors, inhibit tumor angiogenesis, and achieve the effect of “starving” tumors [58,59].”
BackgroundHanum, L., Susyanto, N., & Ertiningsih, D. (2025) · Computational and Mathematical Biophysics · doi:10.1515/cmb-2025-0022 · Cited by 5
“Targeting blood vessels in brain tumors has become an extremely intriguing strategy, considering the high rate of endothelial proliferation, vascular permeability, and expression of proangiogenic growth factors [7].”
BackgroundZhou, L., Li, Y., Wang, L., Chen, K., Zhou, S., Chen, Y., Sun, J., Tong, Y., & Fan, Y. (2025) · Therapeutic Advances in Medical Oncology · doi:10.1177/17588359251348310 · Cited by 5
Angiogenesis and the Tumor Microenvironment
Murphy, J. F. (2022) · Springer eBooks · doi:10.1007/978-3-030-80962-1_87-1 · Cited by 6
Lopes‐Coelho, F., Martins, F., Hipólito, A., Conde, S. V., Pereira, S. A., Gonçalves, L. G., & Serpa, J. (2022) · Biomedicines · doi:10.3390/biomedicines10092293 · Cited by 4
Self-citationBanerjee, N., Roy, L., Panda, S., Roychowdhury, T., & Chatterjee, S. (2024) · Chemical Biology & Drug Design · doi:10.1111/cbdd.70018 · Cited by 4
“Alternatively, the obstruction of the VEGF-VEGFR signalling pathway may stimulate compensatory mechanisms of tumour angiogenesis by increasing the expression levels of other angiogenic factors not targeted by these drugs (Lopes-Coelho et al. 2021).”
Sumer, O. E., Schelzig, K., Jung, J., Li, X., Moros, J., Schwarzmüller, L. E., Şen, E., Karolus, S., Wörner, A., Costa, V. R. D. M., et al. (2025) · BMC Biology · doi:10.1186/s12915-025-02133-x · Cited by 6
Wu, Y., Xie, B.-B., Zhang, B.-L., Zhuang, Q.-X., Liu, S.-W., & Pan, H. (2025) · World Journal of Gastroenterology · doi:10.3748/wjg.v31.i11.102848 · Cited by 4
“As a result, disrupting pathways such as VEGF in endothelial cells has emerged as a viable approach for anti-angiogenic treatments[8].”
Chua, Y. W., & Chow, S. C. (2025) · Acta Tropica · doi:10.1016/j.actatropica.2025.107684 · Cited by 5
Huang, H., Zhao, N., Zhu, J., Li, Q., Qiao, Q., Yang, Y., Zhou, Y., Guo, C., & Guo, Y. (2025) · MedComm · doi:10.1002/mco2.70279 · Cited by 5
“Their clinical effectiveness has also been validated across multiple cancer types [6–10].”
Lenoir, C., Suppa, M., Puig, S., del Mármol, V., Albero‐González, R., Also, L., Cano, C. O., Diet, G., Fontaine, M., Tognetti, L., et al. (2025) · Dermatology Practical & Conceptual · doi:10.5826/dpc.1503a5297 · Cited by 4
Obeagu, E. I. (2025) · Cancer Management and Research · doi:10.2147/cmar.s555874 · Cited by 4
Rahman, A., Jalouli, M., Al-Zharani, M., & Harrath, A. H. (2026) · Biomolecules · doi:10.3390/biom16020246 · Cited by 4
“Anti-angiogenic agents, such as bevacizumab and tyrosine kinase inhibitors, block VEGF signaling and improve blood vessel structure to allow for better infiltration by immune cells [107].”
Targeting VEGFR-2 with piperazine bridged indolin-2-one derivatives
Zengin, M., Arafa, R. K., Küçükkılınç, T. T., & Tan, O. Ü. (2026) · Bioorganic Chemistry · doi:10.1016/j.bioorg.2026.109693 · Cited by 4
Integrins in cancer: insights into mechanisms and therapeutic potential
Agarwal, P., Raman, R., Agarwal, P., Prabhu, V., & Kumar, P. (2026) · Cell Communication and Signaling · doi:10.1186/s12964-026-02828-w · Cited by 4
“Angiogenesis is an essential aspect of tumor growth and maintenance within the TME, as it sustains oxygen and nutrient availability within the tumor niche, due to which it has become a major target of therapies aimed at inhibiting blood vessel formation [129, 130].”
Hanum, L., Ertiningsih, D., & Susyanto, N. (2023) · Electronic Research Archive · doi:10.3934/era.2024004 · Cited by 4
Kheraldine, H., Hassan, A. F., Alhussain, H., Al-Thawadi, H., Vranić, S., & Moustafa, A. A. (2023) · Biomolecules and Biomedicine · doi:10.17305/bb.2023.9869 · Cited by 4
“Antiangiogenic drugs are gaining prominence in the treatment of various pathological conditions, particularly cancer [2].”
BackgroundDeng, W., Chen, J., & Deng, X. (2024) · Frontiers in Immunology · doi:10.3389/fimmu.2024.1333850 · Cited by 4
“Evidence indicates that anlotinib stimulates lymphocyte in fi ltration and migration in tumors, increasing the anticancer effects of PD-L1 inhibitors by reducing immunosuppression (8, 9).”
BackgroundCorsetti, G., Romano, C., Codenotti, S., Giugno, L., Pasini, E., Fanzani, A., Scarabelli, T. M., & Dioguardi, F. S. (2024) · Cells · doi:10.3390/cells13141210 · Cited by 5
“For these reasons, the inhibition of tumor angiogenesis is the target of many antineoplastic therapies [41].”
BackgroundXu, J., Tian, Y., Hu, D., Xi, Y., & Yang, L. (2024) · MedComm – Oncology · doi:10.1002/mog2.85 · Cited by 5
Reciprocal Dynamics of Metabolism and mRNA Translation in Tumor Angiogenesis
Lidonnici, J., & Oberkersch, R. E. (2024) · International Journal of Molecular Sciences · doi:10.3390/ijms252011284 · Cited by 4
“…vessel formation based on reactive oxygen species (ROS) generation, alternative approaches to target tumor angiogenesis are still under study [6,10], now it has become clear that ECs, often di ff erently from other cell types, rely on distinct metabolic pathways to survive and form new blood…”
BackgroundMulti-omics analysis of the biological function of the VEGF family in colon adenocarcinoma
Yang, J., Li, C., Wang, Z., & Jiang, K. (2024) · Functional & Integrative Genomics · doi:10.1007/s10142-024-01493-x · Cited by 6
Boland, P. M., Lenz, H., Ciombor, K. K., Florou, V., Pishvaian, M. J., Cusnir, M., Cohen, D. J., Guo, J. Y., Tang, M., Rajagopalan, P., et al. (2024) · Investigational New Drugs · doi:10.1007/s10637-024-01489-1 · Cited by 11
BZD9L1 benzimidazole analogue hampers colorectal tumor progression by impeding angiogenesis
Oon, C. E., Subramaniam, A. V., Ooi, L. Y., Yehya, A. H. S., Lee, Y. T., Kaur, G., Sasidharan, S., Qiu, B., & Wang, X. (2023) · World Journal of Gastrointestinal Oncology · doi:10.4251/wjgo.v15.i5.810 · Cited by 4
Endothelial cell metabolism: A potential target to improve tumor immunity
Christensen, J. N., Wagman, O., & Kalucka, J. M. (2021) · Current Opinion in Systems Biology · doi:10.1016/j.coisb.2021.100376 · Cited by 5
Rocha, J. L., Pires, F. Q., Gratieri, T., Gelfuso, G. M., Barreto, L. C. L. D. S., & Filho, M. C. (2021) · Thermochimica Acta · doi:10.1016/j.tca.2021.179143 · Cited by 5
Impact of Polypyridyl Ru Complexes on Angiogenesis—Contribution to Their Antimetastatic Activity
Gurgul, I., Mazuryk, O., Stachyra, K., Olszanecki, R., Lekka, M., Łomzik, M., Suzenet, F., Gros, P. C., & Brindell, M. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms23147708 · Cited by 4
Yang, F., Li, H., Hu, X., Fu, R., Li, X., & Li, H. (2024) · Integrative Cancer Therapies · doi:10.1177/15347354241273962 · Cited by 4
“11,12 Bevacizumab and similar drugs exert their effects by inhibiting the VEGF signaling pathway, leading to the pruning of abnormal blood vessels and remodeling of the remaining vasculature, resulting in the establishment of a normalized vascular system.”
BackgroundReversal of Endothelial Cell Anergy by T Cell-Engaging Bispecific Antibodies
Gonçalves, M., Warwas, K. M., Meyer, M., Schwartz‐Albiez, R., Bulbuc, N., Zörnig, I., Jäger, D., & Momburg, F. (2024) · Cancers · doi:10.3390/cancers16244251 · Cited by 4
“However, proper dosing of anti-angiogenic compounds is critical, and combinatorial treatments have been used in order to increase efficacy and avoid drug resistance [9–12].”
Zhang, Z., Li, J., Willis, D., Shi, S., Tu, H., & Costa, M. (2025) · International Journal of Molecular Sciences · doi:10.3390/ijms26094207 · Cited by 3
“In the absence of a blood supply, cancer cells only grow 1–2 mm 3 in size, but they can expand beyond 2 mm 3 where angiogenesis occurs [20].”
Sameh, S., Abdollah, M. R. A., Elissawy, A. M., Al‐Sayed, E., Labib, R. M., Ye, L., Chang, F., & Singab, A. N. B. (2025) · Scientific Reports · doi:10.1038/s41598-025-02717-1 · Cited by 6
“The vascular endothelial growth factor-A (VEGF-A) is considered to be an important angiogenic promoter and is believed to be a potential target for tumor chemoprevention and treatment 5,60 .”
Savage, A. M., Wagner, A. C., Kim, R. T., Gilbert, P., Singer, H. D., Chen, E., Kim, E. M., Lopez, N., Dooling, K. E., Paoli, J. C., et al. (2024) · Developmental Biology · doi:10.1016/j.ydbio.2025.05.030 · Cited by 3
New Insights Into Adipokines and the Tumor Microenvironment in Breast Cancer
Ma, X., Yang, S., & Li, D. (2025) · Cancer Control · doi:10.1177/10732748251347917 · Cited by 7
“63 These newly formed blood vessels not only supply tumor cells with an adequate amount of oxygen and nutrients to satisfy their rapid growth requirements but also offer convenient routes for tumor cells to enter the circulatory system and effectuate distant metastasis.”
Andreana, M., Sentosa, R., Sturtzel, C., Pfister, M., Werkmeister, R. M., Schmitt, A., Traver, D. J., Leitgeb, R. A., Drexler, W., Distel, M., et al. (2025) · Advanced Science · doi:10.1002/advs.202415176 · Cited by 4
Wu, L.-F., Zhang, J.-J., Zhang, X., Wang, D.-P., Zheng, Z.-F., Shen, J., Zhou, Y., Gao, L.-J., Shang, X., Ning, J.-Y., et al. (2025) · Angiogenesis · doi:10.1007/s10456-025-09992-6 · Cited by 4
Yong, G. Y., Lau, B. F., & Kue, C. S. (2025) · Food Bioscience · doi:10.1016/j.fbio.2025.107309 · Cited by 3
Zhao, S., Liu, S., Shao, W., & Liu, D. (2025) · International Journal of Molecular Sciences · doi:10.3390/ijms262211128 · Cited by 4
“Single-cell technology has elucidated the significant heterogeneity of TECs and their intricate interactions with other cellular components within the tumor microenvironment (TME), offering multiple promising targets for the development of novel AAT strategies [46].”
Park, M. J., Jang, J., Park, C. G., Gwak, M., Park, J., & Kim, H. (2026) · Acta Neuropathologica Communications · doi:10.1186/s40478-026-02244-8 · Cited by 3
“Nevertheless, the development of resistance and the limited long-term effectiveness underscore the need to comprehensively clarify the molecular mechanisms underlying tumor angiogenesis, as well as identify new therapeutic targets within endothelial signaling pathways [4].”
Ismail, M. I. B. M., Zainab, fadili, M. E., Ayaz, M., Ahmad, I., Sharif, A., Alam, A., Ahmad, W., Usman, M., Mujwar, S., et al. (2026) · Journal of Molecular Structure · doi:10.1016/j.molstruc.2026.146598 · Cited by 3
Chen, Y.-C., Bollu, V. S., Kheirabadi, S., LaPenna, K. B., Berg, A. S., He, P., Schell, T. D., Sheikhi, A., Tabdanov, E. D., & Robertson, G. P. (2026) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.2602594123 · Cited by 3
In vitro evaluation of the antitumor activity of axitinib in canine mammary gland tumor cell lines
Lee, H. E., Lim, G., An, J., Park, S., Seo, K., & Youn, H. (2023) · Journal of Veterinary Science · doi:10.4142/jvs.23191 · Cited by 3
“Angiogenesis is controlled by different molecules, such as vascular endothelial growth factors (VEGFs), which bind to receptors on endothelial cells within the tumor [9].”
BackgroundTransmembrane modification of tumor vascular targeting peptide A7R as molecular cargo delivery tool
Zhang, Q., Yang, Z., Zhang, J., Li, Y., Dang, X., Qu, J., Pan, X., & Zhang, J. (2024) · Bioorganic Chemistry · doi:10.1016/j.bioorg.2024.107240 · Cited by 3
Fernández-Álvarez, M., Horcajo, P., Jiménez‐Meléndez, A., Lara, P. A., Huertas-López, A., Huertas, F., Ferre, I., Ortega‐Mora, L. M., & Álvarez‐García, G. (2024) · Microorganisms · doi:10.3390/microorganisms12030586 · Cited by 3
“The DEGs and associated pathways identified in infected fibroblasts may serve as invaluable prognostic indicators and potential drug targets for combating fibrosis triggered by B. besnoiti infection (e.g., anti-angiogenic therapies [68–70]).”
BackgroundRegulatory effect of N6-methyladenosine on tumor angiogenesis
Yuyan, & Yuan, E. (2024) · Frontiers in Immunology · doi:10.3389/fimmu.2024.1453774 · Cited by 5
“These abnormalities result in a hypoxic state and the accumulation of metabolic waste within the tumor while also providing nutrients and pathways for tumor cell proliferation and metastasis (2).”
BackgroundMolecules in Motion: Unravelling the Dynamics of Vascularization Control in Tissue Engineering.
Rodrigues, F. A. P., Oliveira, C. S., Sá, S. C., Tavaria, F. K., Lee, S. J., Oliveira, A. L., & Costa, J. B. (2024) · Macromolecular Bioscience · doi:10.1002/mabi.202400139 · Cited by 3
Li, X., Song, W., Engle, J. W., Mixdorf, J. C., Barnhart, T. E., Sun, Y., Zhu, Y., & Cai, W. (2024) · Molecular Pharmaceutics · doi:10.1021/acs.molpharmaceut.4c00983 · Cited by 3
Thromboembolic and bleeding events associated with angiogenesis inhibitors in cancer patients
Ma, Z., Zhang, Y., Sun, D., Zhu, M., Yi, J., Zhang, Y., An, Z., & Zhang, Y. (2025) · Expert Opinion on Drug Safety · doi:10.1080/14740338.2025.2494688 · Cited by 3
Barizi, A. Z. M., Abdullah, M. N. H., Lim, V., & Yong, Y. K. (2025) · Food Bioscience · doi:10.1016/j.fbio.2025.106972 · Cited by 3
General Characteristics and Promotion Properties of Circular PLOD2 in Patients with Glioma
Wu, H., Cheng, L., Sun, W., & Zhou, Y. (2022) · World Neurosurgery · doi:10.1016/j.wneu.2022.10.079 · Cited by 3
Cox, M. C., Mendes, R. G. P. R., Halwachs, K. N., Domenici, G., Brito, C., & Boghaert, E. R. (2023) · Expert Opinion on Drug Discovery · doi:10.1080/17460441.2023.2216016 · Cited by 3
“While this led to the development of anti-angiogenic agents, their success in treating cancer is disappointing [69].”
BackgroundGarcía-Pérez, O., Melgar-Vilaplana, L., Sifaoui, I., Garcia-Bello, M. A., Córdoba-Lanús, E., & Fernández‐de‐Misa, R. (2023) · Melanoma Research · doi:10.1097/cmr.0000000000000904 · Cited by 3
Priya, R. L., Thaiparambil, N. A., Vidya, R., Bhuvaneswari, C., Paunkumar, P., Sudhakaran, R., Kariyanna, B., Karthi, S., & Babu, S. G. (2024) · BioNanoScience · doi:10.1007/s12668-024-01424-x · Cited by 3
Rojas-Solé, C., Torres-Herrera, B., Gelerstein-Claro, S., Medina-Pérez, D., Gómez-Venegas, H., Alzolay-Sepúlveda, J., Chichiarelli, S., Saso, L., & Rodrigo, R. (2024) · Applied Sciences · doi:10.3390/app14114548 · Cited by 3
Luo, Y.-H., Wang, D., Yao, J., Hu, Y., Zhao, L., Wen, J., Zhang, J., Wu, L., Fan, G., & Song, W. (2024) · Frontiers in Microbiology · doi:10.3389/fmicb.2024.1423428 · Cited by 4
Baker, J. H. E., Moosvi, F., Kyle, A. H., Banáth, J. P., Saatchi, K., Häfeli, U. O., Reinsberg, S. A., & Minchinton, A. I. (2023) · Radiotherapy and Oncology · doi:10.1016/j.radonc.2023.109795 · Cited by 3
Kwak, E., Ahmed, T., Flores, P. C., Ortiz, H. R., Langlais, P. R., Mythreye, K., & Lee, N. Y. (2023) · Cancer Medicine · doi:10.1002/cam4.6522 · Cited by 3
Liu, Y., Liang, J., Guo, G.-X., Qiu, Y.-H., Yu, L., Tsim, K. W. K., Qin, Q., Chan, G. K.-L., & Hu, W.-H. (2024) · Chinese Medicine · doi:10.1186/s13020-024-00987-x · Cited by 3
“Therefore, inhibition of VEGF to delay disease progression is considered as a good and highly promising new strategy in the treatment strategy of the above diseases [10, 11].”
BackgroundPrajapati, S., Prajapati, B., Patel, M., & Gupta, R. (2024) · World Academy of Sciences Journal · doi:10.3892/wasj.2024.278 · Cited by 4
Villa, E., Ríos, A., Gutiérrez‐Vidal, R., & Escalante, B. (2024) · PLoS ONE · doi:10.1371/journal.pone.0308075 · Cited by 4
“Thus, the combination of eNOS-siRNA and UMMD may represent an improved anti-angiogenic therapy for NO-dependent disorders associated with increased microvascular permeability and angiogenesis, particularly cancer angiogenesis [44].”
Marcone, S., Spadavecchia, J., Khan, M., Vella, G., O’Connell, F., Pendino, M., Menon, M. S., Donohoe, C. L., Ravi, N., Reynolds, J. V., et al. (2024) · Cancers · doi:10.3390/cancers16234007 · Cited by 2
“Most anti-angiogenic agents approved for cancer treatment target VEGF signalling, given its key role in promoting angiogenesis [52].”
Jansen, S. M., Pitek, R., Karsdal, M. A., & Henriksen, K. (2025) · Journal of Cardiovascular Pharmacology · doi:10.1097/fjc.0000000000001683 · Cited by 2
“3,4 Hence, identifying novel angiogenic therapeutic targets and the development of novel drugs as alternative or combination treatments with existing drugs are needed to improve the survival and quality of life of cancer patients.”
Vasileva‐Slaveva, M., Yordanov, A. D., Ivanov, I., Nanev, V., Chortova, M., Vlahova, A. I., Simeonova, L., Taushanova, M., Calleja‐Agius, J., Harasani, K., et al. (2025) · European Journal of Surgical Oncology · doi:10.1016/j.ejso.2025.109712 · Cited by 2
A primer on metabolic contributions in tumor angiogenic microenvironment
Ocaña, M. C., Bernal, M., Quesada, A. R., & Medina, M. Á. (2025) · Biochimica et Biophysica Acta (BBA) - Reviews on Cancer · doi:10.1016/j.bbcan.2025.189417 · Cited by 5
Li, Z., Wang, Z., Yang, W., Li, Y., Li, Y., & Xu, E. (2025) · Journal of Ethnopharmacology · doi:10.1016/j.jep.2025.120670 · Cited by 3
Al-Jada, D. N., Takruri, H. R., Talib, W. H., Hajeer, M., Alsafadi, D. B., Shahin, N. A., & Ahram, M. A. (2025) · Mediterranean Journal of Nutrition and Metabolism · doi:10.1177/1973798x251391703 · Cited by 2
“60 Tumor cells can upregulate VEGF expression through various stimuli, including cytokines, growth factors, hypoxia, as well as through oncogene activation and tumor suppressor mutation.”
Bi, X., Yang, N., Ke, Y., Xue, J., Zhang, X., Liu, H., Chu, J., Li, L., Shao, Y., Lü, G., et al. (2025) · Frontiers in Microbiology · doi:10.3389/fmicb.2025.1686956 · Cited by 2
Brain tumors: diagnosis and treatment
Dubey, A. K., Shen, B., & Singla, R. K. (2025) · Elsevier eBooks · doi:10.1016/b978-0-443-33910-3.00012-1 · Cited by 2
Akalın, S. A., Afşin, Y., Özdemır, İ., Tuncer, M. C., & Öztürk, Ş. (2025) · Medicina · doi:10.3390/medicina61122181 · Cited by 2
“Hypoxia-inducible factor-1 α (HIF-1 α ) is a key regulator of cellular adaptation to low-oxygen conditions, while vascular endothelial growth factor (VEGF) and its receptor VEGFR2 drive tumor vascularization and correlate with poor prognosis [9].”
Sex-specific angiogenic responses in endothelial cells—role of the pluripotency factor OCT4
Shin, J., Hong, J., Molokotina, I., Krukovets, I., Kim, E., Tkachenko, S., Podrez, E. A., Byzova, T. V., & Cherepanova, O. A. (2025) · Angiogenesis · doi:10.1007/s10456-025-10025-5 · Cited by 2
“However, the clinical efficacy of these trials has been limited, in part due to the tumor necrosis factor α (TNFα)/NFkB-dependent pro-inflammatory effects of VEGF inhibition in ECs, leading to increased immune cell infiltration [ 7] and vascular toxicity, resulting in thrombotic events [8, 9].”
Vu, T. L., Nguyen, T. N. L., Tu, Q. T., Nguyen, D. H., & Hoang Mau, C. H. U. (2026) · Vietnam Journal of Biotechnology · doi:10.15625/vjbt-23376 · Cited by 2
Siromolot, A. A., Zhukova, D. A., Романюк, С. И., Kolybo, D. V., & Komisarenko, S. (2026) · Biochimie · doi:10.1016/j.biochi.2026.02.012 · Cited by 2
Celecoxib: Antiangiogenic and Antitumoral Action
Rojas, V., & Roa, I. (2024) · International Journal of Morphology · doi:10.4067/s0717-95022024000100040 · Cited by 2
Sesărman, A., Lupuţ, L., Rauca, V. F., Pătraș, L., Licărete, E., Meszaros, M. S., Dume, B. R., Negrea, G., Toma, V. A., Muntean, D. M., et al. (2024) · Journal of Liposome Research · doi:10.1080/08982104.2024.2315452 · Cited by 2
Das, K., Sen, J., & Borode, A. S. (2024) · Cureus · doi:10.7759/cureus.67591 · Cited by 2
“Such approaches may lead to more effective management strategies tailored to individual patient profiles, especially in familial cases with a known genetic predisposition [32].”
BackgroundPerspectives for immunotherapy of EBV ‐associated GLELC : A relatively “hot” tumor microenvironment
Lei, Y., Cao, P., Zheng, X., Wei, J., Cheng, M., & Liu, M. (2023) · Cancer Medicine · doi:10.1002/cam4.6555 · Cited by 2
Jasim, S. A., Михайловна, Ф. И., Noraldeen, S. A. M., Bansal, P., Alsaab, H. O., Abdullaev, B., Alkhafaji, A. T., Alawadi, A. H., Hamzah, H. F., & Mohammed, B. A. (2024) · Microvascular Research · doi:10.1016/j.mvr.2024.104691 · Cited by 4
Deng, Z., Zhang, L., Sun, C., Liu, Y., & Li, B. (2024) · Heliyon · doi:10.1016/j.heliyon.2024.e38488 · Cited by 2
Novel Biomarkers in Vascular Diseases: From Discovery to Clinical Translation
Elsaka, O. (2024) · Indian Journal of Vascular and Endovascular Surgery · doi:10.4103/ijves.ijves_42_24 · Cited by 3
Abduljabbar, M. H., Althobaiti, Y. S., Alnemari, R. M., Almutairi, F. M., Aldhafeeri, M. M., Serag, A., & Almalki, A. H. (2024) · Journal of Pharmaceutical and Biomedical Analysis · doi:10.1016/j.jpba.2024.116562 · Cited by 3
USP47 enhances NRP1-mediated angiogenesis to promote gastric cancer progression
Chen, W., Wang, H., Sun, H., Zuo, J., Jiang, P., Feng, W. L., & Huang, Z. (2025) · Biochimica et Biophysica Acta (BBA) - Molecular Cell Research · doi:10.1016/j.bbamcr.2025.120004 · Cited by 2
The apatinib and pemetrexed combination has antitumor and antiangiogenic effects against NSCLC
Zhou, L., Zhang, W., Xiang, Y., Qian, Z., Zhou, J., Ni, L., Feng, Y., & Gao, B. (2023) · Open Life Sciences · doi:10.1515/biol-2022-0533 · Cited by 2
“the pressure between tumor tissues, improve the delivery of chemotherapy drugs to tumor tissues, and improve the chemotherapy effect [8].”
BackgroundMangoni, A. A., Hulin, J.-A., Weerakoon, L., & Tommasi, S. (2023) · Elsevier eBooks · doi:10.1016/b978-0-443-13342-8.00013-2 · Cited by 3
Evaluation of Borax Pentahydrate as a Novel Antiangiogenic AgentPreprint
YILMAZ, H., Özbek, E. N., İşel, E., BÜTÜNER, B. D., Yetik-Anacak, G., Koparal, A. T., & Ulus, G. (2023) · Research Square · doi:10.21203/rs.3.rs-3267555/v1 · Cited by 2
Targeting Angiogenesis in Cancer TherapyPreprint
Wright, K., Sridevan, S., Neupane, A., & Panjiyar, B. K. (2023) · SSRN Electronic Journal · doi:10.2139/ssrn.4648070 · Cited by 2
Protein degradation-based cancer therapy
Avendaño, C., & Menéndez, J. C. (2023) · Elsevier eBooks · doi:10.1016/b978-0-12-818549-0.00012-1 · Cited by 1
Luo, Y., & Ma, X. (2024) · European Journal of Obstetrics & Gynecology and Reproductive Biology · doi:10.1016/j.ejogrb.2024.03.037 · Cited by 1
Impact of angiogenesis inhibitors on inflammatory activation in human vascular endothelial cells
Piekarska, K., Spyt, D., Bonowicz, K., Jerka, D., Grzanka, A., & Gagat, M. (2024) · Medical Research Journal · doi:10.5603/mrj.101643 · Cited by 2
“These are therapies based on substances that recognize and inhibit the activity of VEGF factors, such as bevacizumab, pazopanib, and KRN-633 [19, 20].”
Tumor Vasculature Effects of High-Dose Radiation Therapy
Sharma, D., Leong, K. X., & Czarnota, G. J. (2024) · Springer eBooks · doi:10.1007/978-3-031-67743-4_1 · Cited by 1
Eugenol inhibits NEAT1 as a ceRNA in pre-cancerous breast lesions
Liu, Y., Zhang, G., Ma, Y., Ma, M., & Jiang, X. (2024) · Heliyon · doi:10.1016/j.heliyon.2024.e41353 · Cited by 1
Borax pentahydrate as a promising boron-based angiogenesis inhibitor
Ulus, G., Özbek, E. N., Yılmaz, H., Keselik, E., Sarıcaoğlu, M., Bahçeci, S., İşel, E., BÜTÜNER, B. D., Yetik-Anacak, G., & Koparal, A. T. (2025) · Journal of Trace Elements in Medicine and Biology · doi:10.1016/j.jtemb.2025.127640 · Cited by 1
Altaf, R. R. S., Venkatesan, P., Palani, N., Mendonce, K. C., Mohan, A., Nithya, T. G., Srinivasan, M., Rajendran, S., Surya, P., & Rajadesingu, S. (2025) · Journal of Superconductivity and Novel Magnetism · doi:10.1007/s10948-025-07047-x · Cited by 1
Li, Y., & Ouyang, L. (2025) · Elsevier eBooks · doi:10.1016/b978-0-443-33885-4.00023-8 · Cited by 1
Huang, N., Sun, N., Yang, H., Wang, R., Li, L., Tao, J., Feng, Q., & Chen, Z. (2025) · Scientific Reports · doi:10.1038/s41598-025-29844-z · Cited by 1
“Angiogenesis is the process by which vascular endothelial cells proliferate and migrate to form new capillary networks, with VEGF recognized as the most crucial pro-angiogenic factor during wound healing 25 .”
Chen, Z., Liao, Q., Zhao, P., Geng, Y., Wen, J., Liu, S., Tang, Y., Zeng, C., Yan, T., Shen, Y., et al. (2025) · Medicinal Chemistry Research · doi:10.1007/s00044-025-03511-4 · Cited by 1
“Research indicates that neovascularization is intricately linked to tumor progression and has a substantial impact on patient prognoses [28, 29].”
A novel angiogenesis-related gene signature predicting prognosis in clear cell renal cell carcinoma
Xu, Y., Cheng, G.-B., Li, X., Zeng, X., & Wu, S. (2025) · Scientific Reports · doi:10.1038/s41598-025-30376-9 · Cited by 3
Díaz, Y. M., García-Sanmartín, J., Canaán-Haden, C., Béquet‐Romero, M., González-Moya, I., Ayala‐Ávila, M., Tadic, S., Garrido, P., Narro-Íñiguez, J., Fuentes-Morales, D., et al. (2025) · Frontiers in Immunology · doi:10.3389/fimmu.2025.1667651 · Cited by 1
Conti, P., Gallenga, C. E., Annicchiarico, C., Coppola, A., Pellegrino, R., Conti, M. J., & Mastrangelo, F. (2026) · International Journal of Molecular Sciences · doi:10.3390/ijms27020824 · Cited by 2
“In the breast cancer microenvironment, an angiogenic process occurs among tumor cells, with new blood vessel formation and the presence of various cell types, including fibroblasts, stem cells, and white blood immune cells [13].”
Santoni, F. M., Ciccone, V., Flaccavento, A., Morbidelli, L., Ziche, M., Tuccori, M., Spini, A., & Donnini, S. (2026) · European Journal of Clinical Pharmacology · doi:10.1007/s00228-025-03929-0 · Cited by 1
Ravichandran, A., Upton, K. R., Taheri, S., Liu, C., Ferguson, K., Adams, M. N., & Bray, L. J. (2026) · Clinical & Experimental Metastasis · doi:10.1007/s10585-026-10391-4 · Cited by 1
“Inhibition of angiogenesis has been shown to activate compensatory pro-angiogenic mechanisms and pathways that protect the vascular supply to the tumours [25].”
Metadata
- Authors
- Lopes-Coelho, F., Martins, F., Pereira, S. A., & Serpa, J.
- Affiliations
- Instituto Português de Oncologia de Lisboa Francisco Gentil (IPOLFG), Rua Prof. Lima Basto, 1099-023 Lisboa, Portugal
- Instituto Português de Oncologia Francisco Gentil (PT)
- Universidade Nova de Lisboa (PT)
- Corresponding author
- Serpa, Jacinta
- Venue
- International Journal of Molecular Sciences
- Publisher
- MDPI AG
- Published
- 2021-04-05
- Volume
- 22
- Issue
- 7
- Pages
- 3765
- ISSN
- 1422-0067 (ISSN-L)
- PMC
- PMC8038573
- OpenAlex
- W3140967360
- Cited by
- 416
- References
- 246
- Citations by year
- 2026: 61 · 2025: 98 · 2024: 117 · 2023: 86 · 2022: 46 · 2021: 8
- FWCI
- 6.77
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Licence
- Locations
- International Journal of Molecular Sciences (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- Portuguese National Funding Agency for Science, Research and Technology (RCAAP Project by FCT) (submittedVersion, other-oa)
- DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
- Funders
- Ministério da Educação e Ciência
- Ministério da Ciência, Tecnologia e Ensino Superior
- Ministério da Educação
- Fundação para a Ciência e a Tecnologia (/2017, iNOVA4Health, PD/BD/128337/2017)
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Angiogenesis and VEGF in Cancer
- Health Sciences › Medicine › Oncology › Lymphatic System and Diseases
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › Cancer, Hypoxia, and Metabolism
- Keywords
- anti-angiogenic therapy, angiogenesis, VEGF signaling, tumor microenvironment, cancer immunotherapy, immunosuppression, drug repurposing, combination therapy, tumor vasculature, treatment resistance
- MeSH terms
- Animals, Humans, Neoplasm Proteins, Neoplasms, Neovascularization, Pathologic, Angiogenesis Inhibitors, Vascular Endothelial Growth Factor A, Tumor Microenvironment
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.